151 related articles for article (PubMed ID: 32433863)
1. Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.
Faber EB; Tian D; Burban D; Levinson NM; Hawkinson JE; Georg GI
ACS Chem Biol; 2020 Jul; 15(7):1759-1764. PubMed ID: 32433863
[TBL] [Abstract][Full Text] [Related]
2. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to the discovery of small-molecule ligands of CDK2.
Martin MP; Alam R; Betzi S; Ingles DJ; Zhu JY; Schönbrunn E
Chembiochem; 2012 Sep; 13(14):2128-36. PubMed ID: 22893598
[TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a potential allosteric ligand binding site in CDK2.
Betzi S; Alam R; Martin M; Lubbers DJ; Han H; Jakkaraj SR; Georg GI; Schönbrunn E
ACS Chem Biol; 2011 May; 6(5):492-501. PubMed ID: 21291269
[TBL] [Abstract][Full Text] [Related]
6. Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding.
Faber EB; Sun L; Tang J; Roberts E; Ganeshkumar S; Wang N; Rasmussen D; Majumdar A; Hirsch LE; John K; Yang A; Khalid H; Hawkinson JE; Levinson NM; Chennathukuzhi V; Harki DA; Schönbrunn E; Georg GI
Nat Commun; 2023 Jun; 14(1):3213. PubMed ID: 37270540
[TBL] [Abstract][Full Text] [Related]
7. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
8. Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice.
Faber EB; Wang N; John K; Sun L; Wong HL; Burban D; Francis R; Tian D; Hong KH; Yang A; Wang L; Elsaid M; Khalid H; Levinson NM; Schönbrunn E; Hawkinson JE; Georg GI
J Med Chem; 2023 Feb; 66(3):1928-1940. PubMed ID: 36701569
[TBL] [Abstract][Full Text] [Related]
9. Targeting Conformational Activation of CDK2 Kinase.
Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis.
Qin M; Xin Y; Bian Y; Yang X; Xi T; Xiong J
Cells; 2022 Jan; 11(2):. PubMed ID: 35053380
[TBL] [Abstract][Full Text] [Related]
11. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
12. ANS Interacts with the Ca
De la Cruz-Torres V; Cataño Y; Olivo-Rodríguez M; Sampedro JG
J Fluoresc; 2020 May; 30(3):483-496. PubMed ID: 32146650
[TBL] [Abstract][Full Text] [Related]
13. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
Abdalla AN; Abdallah ME; Aslam A; Bader A; Vassallo A; Tommasi N; Malki WH; Gouda AM; Mukhtar MH; El-Readi MZ; Alkahtani HM; Abdel-Aziz AA; El-Azab AS
Molecules; 2020 May; 25(9):. PubMed ID: 32397330
[TBL] [Abstract][Full Text] [Related]
15. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
16. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M; Luciani MG; Finlan L; Rankin EM; Ibbotson S; Fersht A; Hupp TR
Cell Cycle; 2004 Jan; 3(1):80-9. PubMed ID: 14657672
[TBL] [Abstract][Full Text] [Related]
17. Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention.
Dachineni R; Ai G; Kumar DR; Sadhu SS; Tummala H; Bhat GJ
Mol Cancer Res; 2016 Mar; 14(3):241-52. PubMed ID: 26685215
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.
Rath SL; Senapati S
PLoS One; 2013; 8(9):e73836. PubMed ID: 24058495
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
